Including genetic criteria, especially the clonal architecture, in leukemia classification will allow pathologists to identify the type of cancer being treated at a molecular level. This will allow clinicians to select certain drugs and avoid others based on disease type and make a more accurate prognosis for the course of the disease.
On caring for a patient with a loving family, limited treatment options and cognitive differences in the solitary times of COVID-19.
When Blood Breaks Down: Life Lessons from Leukemia, the new book by Cleveland Clinic oncologist Mikkael Sekeres, MD, MS, is a forthright, informative and moving account of what it’s like to be a leukemia patient and a leukemia doctor.
Remission rates of elderly ALL patients on a novel, lower-toxicity immunotherapy regimen appear to at least equal those observed with conventional chemotherapy.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Study leads to FDA-approval of ivosidenib for patients with relapsed or refractory acute myeloid leukemia that have the genetic mutation IDH1.
Researchers uncover how the mutated NPM1 gene actually causes acute myeloid leukemia (AML). Their findings pave the way for targeted therapy for this largest subgroup of AMLs.
A new study shows that physicians may be overtreating patients with well-differentiated thyroid cancer and putting them at risk for more deadly diseases.
Patients with relapsed/refractory ALL who were treated in a clinical trial with the antibody-drug conjugate inotuzumab ozogamicin experienced much higher remission rates compared with the standard of care, a new study reports.
The prognosis for ALL is poor and therapy has not changed for a decade. The drug inotuzumab ozogamicin now holds promise to change that outlook and improve outcomes.
Cleveland Clinic researchers have identified gene mutations in some aplastic anemia patients that are associated with progression to myelodysplastic syndrome and/or acute myeloid leukemia. The mutations may trigger the immune response that results in aplastic anemia, and may also help mutated hematopoietic cells further proliferate.